# Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients

> **NIH NIH K23** · JOHNS HOPKINS UNIVERSITY · 2022 · $175,913

## Abstract

Over 1/3 of adolescents and young adults (AYAs) who have undergone kidney or liver transplantation are
nonadherent to immunosuppressant medicine, a leading cause of organ rejection, graft failure, and death.
Despite the American Society of Transplantation's calls for real-time approaches to address immunosuppressant
nonadherence, there are no validated metrics using real-time adherence data (e.g., electronic pillboxes) to
identify those at risk for rejection and no efficacious interventions that leverage these data to improve adherence.
Hence, we will fill these critical gaps in nonadherence management by validating the new “Real-Time Adherence
Measure,” a novel instrument that could revolutionize how nonadherence is detected by linking the precision of
non-invasive, easily downloaded, timestamped electronic pillbox data to tacrolimus blood level standard
deviations (biological index of drug ingestion) to direct in the moment when immunosuppressant nonadherence
leads to rejection. We will harness this real-time daily dosing information in an adherence-promoting just-in-time
adaptive intervention (JITAI), a cutting-edge mobile health approach capable of fully incorporating AYAs' daily
electronically-monitored adherence to deliver tailored intervention content exactly when the AYA needs it most.
Currently, there are no JITAIs for this purpose. We will conduct this vital research, which involves using a micro-
randomized trial, a state-of-the-art experimental design for creating successful JITAIs. To develop our JITAI, we
will modify a promising existing intervention for promoting AYA adherence (sent adherence support messages
when dose was due) by triggering adherence support messages only when medicine is missed and providing
praise messages when medicine is taken. A JITAI-version of this intervention will be piloted with AYA kidney or
liver transplant recipients in a 12-week micro-randomized trial to identify intervention content and timing that
maximize the JITAI's impact on adherence. AYAs will be randomized after each electronically-monitored missed
tacrolimus dose to receive (1) an adherence support message or (2) no message. After each on time dose, AYAs
will be randomized to receive (1) a praise message or (2) no message. AYAs' engagement in the JITAI will be
qualitatively characterized to support long-term uptake. Our findings will address significant knowledge gaps in
how to optimally leverage technology to effectively measure and improve medication adherence for AYA kidney
or liver transplant recipients, reduce nonadherence-related rejection, graft loss, and death, and improve people's
health and quality of life. Dr. Eaton's study and training activities will prepare her to use advanced methodologies
to validate novel clinical metrics, design JITAIs, conduct micro-randomized trials, and improve mobile health
engagement. It is critical for Dr. Eaton to have support from this K23 to attain expertise in these innovative
methods and to achie...

## Key facts

- **NIH application ID:** 10487516
- **Project number:** 5K23DK128573-02
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Cyd Kumiko Eaton
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $175,913
- **Award type:** 5
- **Project period:** 2021-09-15 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10487516

## Citation

> US National Institutes of Health, RePORTER application 10487516, Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients (5K23DK128573-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10487516. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*